ALGS Stock Analysis: Buy, Sell, or Hold?
ALGS - Aligos Therapeutics, Inc. Common Stock
$4.60
0.37 (8.75%)
▲
5d:
+12.75%
30d:
-17.71%
90d:
-24.47%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When ALGS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ALGS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ALGS shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ALGS is currently trading at $4.60, which is considered slightly low relative to its 30-day fair value range of $4.56 to $6.21.
Technical Outlook: Technically, ALGS is in a strong downtrend. Immediate support is located at $3.98, while resistance sits at $5.80. The stock is showing strong short-term momentum, up 8.7% recently.
Market Sentiment: ALGS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $56.29 (+1123.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ALGS is in a strong downtrend. Immediate support is located at $3.98, while resistance sits at $5.80. The stock is showing strong short-term momentum, up 8.7% recently.
Market Sentiment: ALGS has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $56.29 (+1123.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$4.56 -
$6.21
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+8.7%)
- BULLISH: Trading 1123.6% below Wall St target ($56.29)
Trading Range Analysis
30-Day Trading Range
$4.56 -
$6.21
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.98
Resistance Level
$5.80
Current Trend
Strong Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.15
Wall Street Target
$56.29
(+1123.6%)
Revenue Growth (YoY)
810.0%
Share & Embed Analysis
Last updated: August 04, 2026 3:16 AM ET
Data refreshes hourly during market hours. Next update: 4:16 AM
Data refreshes hourly during market hours. Next update: 4:16 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ALGS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$89 | 59 HOLD |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$53 | 57 HOLD |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 53 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 57 HOLD |
